Object structure
Title:

Antisense Oligonucleotides to PAM mRNA as Potential Agents for Therapeutic Intervention in Cardiovascular Diseases

Subtitle:

Antisense Oligonucleotides to PAM mRNA as Potential Agents for Therapeutic Intervention in Cardiovascular Diseases

Creator:

Cierniewski, Czesław S. ; Pawłowska, Zofia ; Pluskota, Elżbieta ; Stasiak, Marta ; Kobylańska, Anna ; Misiura, Konrad ; Maciaszek, Anna ; Koziołkiewicz, Maria ; Stec, Wojciech J.

Publisher:

Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS

Date issued/created:

1996

Description:

Polish - Japan Issue

Subject and Keywords:

biotechnology

Abstract:

Thrombolytic therapy provides clinical benefit in patients with vascular occlusions, dependingupon the organ or limb that is threated. The impact of therapeutic intervention varies from thequiet alteration of the course of deep vein thrombosis, for which non-life threatening postphlebitic syndrome can largely be avoided, to the striking reversal of pulmonary hypertensionand possible life-saving benefit in massive pulmonary embolism, the immediate alteration ofclinical course in acute peripheral arterial occlusion by reducing the need for surgical intervention, cardiopulmonary complication and one year mortality, and finally to the dramatic andlife-saving potential when applied in patients with acute myocardial infarction. At least threealternative and complementary approaches to improve thrombolytic therapy can be distinguished:a) earlier and accelerated treatment in order to reduce the duration of ischemia, b) developmentof alterative or engineered plasminogen activators with increased thrombolytic potency and/orspecific thrombolytic activity, in order to enhance coronary thrombolysis, and c) the use of morespecific and potent anticoagulant and antiplatelet agents for conjunctive use with thrombolyticagents, with the aim to accelerate recanalization and prevent reocclusion. In this report wediscuss the possibility of using antisense oligonucleotides specific to PAJ-l mRNA to reversiblydecrease PAI-1 level in blood plasma and thus prolong a half-life time of endogenous plasminogenactivators in circulation.

Relation:

Biotechnologia, vol.35, 4 (1996)-.

Volume:

35

Issue:

4

Start page:

141

End page:

152

Resource type:

Text

Detailed Resource Type:

Article

Format:

application/pdf

Resource Identifier:

0860-7796 ; IChB B-31

Source:

Library of Institute of Bioorganic Chemistry PAS

Language:

eng

Language of abstract:

eng

Temporal coverage:

1988-2010

Rights:

Creative Commons Attribution BY-SA 4.0 license

Terms of use:

Copyright-protected material. [CC BY-SA 4.0] May be used within the scope specified in Creative Commons Attribution BY-SA 4.0 license, full text available at:

Digitizing institution:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Original in:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Projects co-financed by:

Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.

Access:

Open

×

Citation

Citation style: